{"id":"lobaplatin-5-fu-leucovorin","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-15%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lobaplatin is a second-generation platinum compound that has been shown to be more potent than cisplatin in some preclinical studies. It is thought to exert its antitumor effects by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.","oneSentence":"Lobaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:16.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT02973685","phase":"PHASE3","title":"HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-10-01","conditions":"HepatoCellular Carcinoma","enrollment":315},{"nctId":"NCT03048123","phase":"PHASE2","title":"HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-10-01","conditions":"Hepatocellular Carcinoma","enrollment":79},{"nctId":"NCT01034683","phase":"PHASE3","title":"Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma","status":"UNKNOWN","sponsor":"Taian Cancer Hospital","startDate":"2009-12","conditions":"Esophageal Carcinoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LBP ,5-FU,LV"],"phase":"phase_3","status":"active","brandName":"lobaplatin , 5-FU ,leucovorin","genericName":"lobaplatin , 5-FU ,leucovorin","companyName":"Taian Cancer Hospital","companyId":"taian-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lobaplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Metastatic colorectal cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}